Biology-First AI platform predicts disease-matched compounds using multi-omics human data and functional validation.
The Biology-First AI platform analyzes multi-omics human disease data to predict compounds matched to disease subtypes. It tests a focused set of predicted candidates through deep functional validation before advancing them toward development.
Pharmaceutical and biotechnology research teams use the platform for oncology and complex-disease programs. Discovery partnerships include a gastrointestinal-toxicity program with Roche and collaboration work with POLARISqb.
Generate Biomedicines
Generate Platform
generatebiomedicines.com
Insilico Medicine
Pharma.ai
insilico.com
Recursion Pharmaceuticals
Recursion OS
recursion.com
| Attribute | Auransa Biology-First AI Platform | Generate Platform | Pharma.ai | Recursion OS | |
|---|---|---|---|---|---|
| Provider |  | | | | |
| Founded | 2014 | 2018 | 2014 | 2013 | |
| Sells To | Enterprise | Enterprise | Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Recurring, Software | Recurring, Software | Recurring, Software | |
| Ownership | Venture-backed | Equity, Venture-backed | Venture-backed | Public, Venture-backed |
Provider
Founded 2014
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
Provider
Founded 2018
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Equity, Venture-backed
Provider
Founded 2014
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
Provider
Founded 2013
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public, Venture-backed
Biomedical AI platform that grounds biopharma R&D decisions in validated biology.
Machine learning platform for drug discovery and development.
Allosteric screening and synthetic lethality platforms with 200k library.
A tissue-first platform generating spatial, molecular, and functional maps from patient tumors.
Compass is Inductive Bio virtual bench platform embedding AI models, lab automation, and chemists in small-molecule discovery.
Drug discovery platform from Tango Therapeutics that identifies synthetic lethal targets using CRISPR-based functional genomics screening.
mBER is Manifold Bio's open-source AI framework for designing antibody binders for in vivo drug discovery.
EVA combines machine learning and automated laboratory testing to optimize therapeutic antibodies.
Cyrus Platform is Cyrus Biotechnology's computational protein design offering combining AI and Rosetta-based design with laboratory mutagenesis screening.
AI-enabled natural-product drug discovery platform organizing plant chemistry into a searchable library with machine-learning translation and automated screening.
Biomedical AI platform that grounds biopharma R&D decisions in validated biology.
Machine learning platform for drug discovery and development.
Allosteric screening and synthetic lethality platforms with 200k library.
A tissue-first platform generating spatial, molecular, and functional maps from patient tumors.
Compass is Inductive Bio virtual bench platform embedding AI models, lab automation, and chemists in small-molecule discovery.
Agentic AI platform for RNA drug discovery covering ASO and siRNA design through lead optimization.
D360 is a scientific informatics platform that accelerates drug discovery data analysis and collaboration.
Drug discovery platform from Tango Therapeutics that identifies synthetic lethal targets using CRISPR-based functional genomics screening.
mBER is Manifold Bio's open-source AI framework for designing antibody binders for in vivo drug discovery.
EVA combines machine learning and automated laboratory testing to optimize therapeutic antibodies.
Cyrus Platform is Cyrus Biotechnology's computational protein design offering combining AI and Rosetta-based design with laboratory mutagenesis screening.
AI-enabled natural-product drug discovery platform organizing plant chemistry into a searchable library with machine-learning translation and automated screening.